Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropins
- PMID: 37007338
- PMCID: PMC10063211
- DOI: 10.7759/cureus.35601
Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropins
Erratum in
-
Correction: Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropins.Cureus. 2025 Sep 11;17(9):c290. doi: 10.7759/cureus.c290. eCollection 2025 Sep. Cureus. 2025. PMID: 40949079 Free PMC article.
Abstract
Background Hypogonadotropic hypogonadism is an important cause of male infertility and loss of secondary sexual characteristics. Gonadotropin replacement is mandatory for sexual function, bone health, and normal psychological status. This study is to compare the effectiveness of different gonadotropin therapy modalities in the management of male hypogonadism. Methods A randomized open-label prospective study of 51 patients attended the Faiha Specialized Diabetes, Endocrine and Metabolism Center (FDEMC) with hypogonadotropic hypogonadism, divided randomly into three groups. The first group was treated with human chorionic gonadotropin (hCG) alone, the second group was treated with a combination of both hCG and human menopausal gonadotropin (HMG), while the third group started with hCG alone then followed by combination therapy after six months. Results All modalities of therapy result in a significant increase in mean testicular volume although no clinically significant difference between the groups, but the combination group had the highest increment. The increment in serum testosterone level was statistically significant among the different groups of treatment (p-value < 0.0001). When comparing groups, a higher mean maximum testosterone level (710.4±102.7 ng/dL) was obtained with the combination group followed by the sequential group, with mean maximum testosterone levels (636.0±68.6 ng/dL) (p-value = 0.031). Factors negatively affecting testosterone level include BMI > 30 kg/m2, initial testicular volume < 5 mL, and duration of therapy < 13 months. Conclusions Induction of puberty using recombinant hCG alone is sufficient to induce secondary sexual characteristics, while for fertility issues combination from the start or sequential therapy has better for spermatogenesis. There was no effect of prior exogenous testosterone treatment on final spermatogenesis.
Keywords: gonadotropins; hypogonadotropic hypogonadism; iraq; male hypogonadism; spermatogenesis.
Copyright © 2023, Sahib et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
References
-
- Hypogonadism: therapeutic risks, benefits, and outcomes. Sigalos JT, Pastuszak AW, Khera M. Med Clin North Am. 2018;102:361–372. - PubMed
-
- Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. Gray A, Feldman HA, McKinlay JB, Longcope C. J Clin Endocrinol Metab. 1991;73:1016–1025. - PubMed
-
- Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. Boehm U, Bouloux PM, Dattani MT, et al. Nat Rev Endocrinol. 2015;11:547–564. - PubMed
-
- The epidemiology of male infertility. Winters BR, Walsh TJ. Urol Clin North Am. 2014;41:195–204. - PubMed
LinkOut - more resources
Full Text Sources